Extract
We read with interest the report of the results of the COPE-III trial by Lenferink et al. [1]. This large randomised trial continues on from the authors’ earlier COPE-II study [1], with personalised exacerbation action plans based on associated comorbidities. The action plans were detailed, and designed to determine symptom changes and the signs of an ensuing exacerbation. The study was negative for its primary endpoint (COPD exacerbation days) and no improvement in quality of life was found using the self-management intervention.
Abstract
COPD exacerbation self-management does not reduce COPD exacerbation days or hospitalisation, rather to more oral corticosteroid use and is rarely effective as it is not targeted http://bit.ly/33D89jF
Footnotes
Conflict of interest: S. Ramakrishnan reports non-financial (travel) support from AstraZeneca, outside the submitted work.
Conflict of interest: M. Bafadhel reports grants from AZ, personal fees for consulting and advisory boards, and support for travel to conferences from AZ, Chiesi and GSK, outside the submitted work.
- Received October 28, 2019.
- Accepted October 31, 2019.
- Copyright ©ERS 2020